Standard Doses of Cholecalciferol Reduce Glucose and Increase Glutamine in Obesity-Related Hypertension: Results of a Randomized Trial

被引:0
|
作者
Santos, Catarina [1 ,2 ]
Carvalho, Rui [3 ]
Fonseca, Ana Mafalda [4 ]
Castelo Branco, Miguel [1 ,4 ]
Alves, Marco [5 ,6 ,7 ]
Jarak, Ivana [8 ,9 ]
机构
[1] Univ Beira Interior, Hlth Sci Fac, P-6200505 Covilha, Portugal
[2] Castelo Branco Local Hlth Unit, Nephrol Dept, P-6000128 Castelo Branco, Portugal
[3] Univ Coimbra, Fac Sci & Technol, Dept Life Sci, Coimbra, Portugal
[4] Univ Beira Interior, Invest Ctr Hlth Sci, CICS UBI, P-6200505 Covilha, Portugal
[5] Univ Porto, ICBAS Sch Med & Biomed Sci, UMIB Unit Multidisciplinary Res Biomed, Lab Endocrine & Metab Res, P-4050313 Porto, Portugal
[6] Univ Porto, Lab Integrat & Translat Res Populat Hlth ITR, P-4200465 Porto, Portugal
[7] Univ Porto, ICBAS Sch Med & Biomed Sci, Dept Immuno Physiol & Pharmacol, Lab Physiol, P-4050313 Porto, Portugal
[8] Univ Coimbra, Fac Pharm, Lab Drug Dev & Technol, P-3000548 Coimbra, Portugal
[9] Univ Porto, i3S Inst Invest & Hlth Innovat, P-4200393 Porto, Portugal
关键词
vitamin D; hypertension; glutamine; obesity; metabolites; glucose; VITAMIN-D SUPPLEMENTATION; 1,25-DIHYDROXYVITAMIN D-3; IN-VITRO; MTOR; METABOLISM;
D O I
10.3390/ijms25063416
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In arterial hypertension, the dysregulation of several metabolic pathways is closely associated with chronic immune imbalance and inflammation progression. With time, these disturbances lead to the development of progressive disease and end-organ involvement. However, the influence of cholecalciferol on metabolic pathways as a possible mechanism of its immunomodulatory activity in obesity-related hypertension is not known. In a phase 2, randomized, single-center, 24-week trial, we evaluated, as a secondary outcome, the serum metabolome of 36 age- and gender-matched adults with obesity-related hypertension and vitamin D deficiency, before and after supplementation with cholecalciferol therapy along with routine medication. The defined endpoint was the assessment of circulating metabolites using a nuclear magnetic resonance-based metabolomics approach. Univariate and multivariate analyses were used to evaluate the systemic metabolic alterations caused by cholecalciferol. In comparison with normotensive controls, hypertensive patients presented overall decreased expression of several amino acids (p < 0.05), including amino acids with ketogenic and glucogenic properties as well as aromatic amino acids. Following cholecalciferol supplementation, increases were observed in glutamine (p < 0.001) and histidine levels (p < 0.05), with several other amino acids remaining unaffected. Glucose (p < 0.05) and acetate (p < 0.05) decreased after 24 weeks in the group taking the supplement, and changes in the saturation of fatty acids (p < 0.05) were also observed, suggesting a role of liposoluble vitamin D in lipid metabolism. Long-term cholecalciferol supplementation in chronically obese and overweight hypertensives induced changes in the blood serum metabolome, which reflected systemic metabolism and may have fostered a new microenvironment for cell proliferation and biology. Of note, the increased availability of glutamine may be relevant for the proliferation of different T-cell subsets.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Public Reactions to Obesity-Related Health Campaigns A Randomized Controlled Trial
    Puhl, Rebecca
    Luedicke, Joerg
    Peterson, Jamie Lee
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2013, 45 (01) : 36 - 48
  • [2] Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial
    He, Hongbo
    Zhao, Zhigang
    Chen, Jing
    Ni, Yinxing
    Zhong, Jian
    Yan, Zhencheng
    Li, Yingsha
    Liu, Daoyan
    Pletcher, Mark J.
    Zhu, Zhiming
    [J]. JOURNAL OF HYPERTENSION, 2012, 30 (07) : 1430 - 1439
  • [3] Effects of orlistat on obesity-related diseases -: a six-month randomized trial
    Guy-Grand, B
    Drouin, P
    Eschwège, E
    Gin, H
    Joubert, JM
    Valensi, P
    [J]. DIABETES OBESITY & METABOLISM, 2004, 6 (05): : 375 - 383
  • [4] A randomized trial to reduce obesity in Hispanic youths: Methods and baseline results
    Roberts, JM
    Pavlik, V
    Goodrick, K
    [J]. OBESITY RESEARCH, 2005, 13 : A189 - A189
  • [5] Cholecalciferol Treatment to Reduce Blood Pressure in Older Patients With Isolated Systolic Hypertension The VitDISH Randomized Controlled Trial
    Witham, Miles D.
    Price, Rosemary J. G.
    Struthers, Allan D.
    Donnan, Peter T.
    Messow, Claudia-Martina
    Ford, Ian
    McMurdo, Marion E. T.
    [J]. JAMA INTERNAL MEDICINE, 2013, 173 (18) : 1672 - 1679
  • [6] Randomized Controlled Trial Targeting Obesity-Related Behaviors: Better Together Healthy Caswell County
    Zoellner, Jamie
    Hill, Jennie L.
    Grier, Karissa
    Chau, Clarice
    Kopec, Donna
    Price, Bryan
    Dunn, Carolyn
    [J]. PREVENTING CHRONIC DISEASE, 2013, 10
  • [7] The impacts of multiple obesity-related interventions on quality of life in children and adolescents: a randomized controlled trial
    Hua Diao
    Hong Wang
    Lianjian Yang
    Ting Li
    [J]. Health and Quality of Life Outcomes, 18
  • [8] The impacts of multiple obesity-related interventions on quality of life in children and adolescents: a randomized controlled trial
    Diao, Hua
    Wang, Hong
    Yang, Lianjian
    Li, Ting
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2020, 18 (01)
  • [9] Orange juice allied to a reduced-calorie diet results in weight loss and ameliorates obesity-related biomarkers: A randomized controlled trial
    Ribeiro, Carolina
    Dourado, Grace
    Cesar, Thais
    [J]. NUTRITION, 2017, 38 : 13 - 19
  • [10] A Randomized Trial of Laparoscopic Bariatric Surgery in Patients with Obesity-Related Type 2 Diabetes Mellitus: Preliminary One-Year Results
    Chen, Chih-Yen
    Lee, Wei J.
    Lee, Shou-Dong
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : A385 - A385